

CERTIFICATE OF ANALYSIS

Important Note: Centrifuge before opening to ensure complete recovery of vial contents.

Catalog #: K23001R **Lot #:** 1K30919
Page 1 of 2

Description: Rabbit anti Apo AI, Mouse
Rabbit Antibody to Mouse Apolipoprotein AI (Apo AI)

Specificity: Recognizes mouse and rat Apo AI. Does not react well with human Apo AI.

Host Animal: Rabbit

Immunogen: Purified mouse apolipoprotein AI from pooled mouse plasma high density lipoprotein.

Format: Affinity Purified, Liquid

Purification: Immunoaffinity Chromatography

Concentration: 1 mg/mL
Titer: 1:500

Buffer: 10 mM Tris, 0.15 M Sodium Chloride, 1 mM EDTA, pH 8.0.

Preservative: 0.02% Sodium Azide

Applications: Suitable for use in Radial Immunodiffusion, Western Blot and ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

Storage: Store (up to 1 year) at 2–8°C. **DO NOT FREEZE.**

Safety Notes(s): Refer to the appropriate Safety Data Sheet (SDS) for additional information.

Catalog #K23001R

Page 2 of 2

References:

The references listed below are for research purposes only:

1. Basso, F., et al., (2007), "Hepatic ABCG5/G8 Overexpression Reduces apoB-lipoproteins and Atherosclerosis When Cholesterol Absorption is Inhibited", J. Lipid Res., **48**:114-126.
2. Brown, R.J., et al., (2004), "Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan", The Journal of Biological Chemistry, **279**(41): 42403-42409.
3. Conde-Knape, K., et al., (2002), "Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase", J. Lipid Res., **43**: 2136-2145.
4. Fagan, A.M., et al., (2004), "ApoAI Deficiency Results in Marked Reduction in Plasma Cholesterol But no Alterations in Amyloid-beta Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis", American Journal of Pathology, **165**(4): 1413-1422.
5. Frank, P.G., et al., (2004), "Genetic Ablation of Caveolin-1 Confers Protection Against Atherosclerosis", Arterioscler Thromb. Vasc. Biol., **24**: 98-105.
6. Gruen, M.L., et al., (2005), "Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I, J. Lipid Res., **46**: 2007-2014.
7. Navab, M., et al., (2003), "Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E-Null Mice", Circulation, **108**: 1735-1739.

Beverly L. Orr

04 January 2020

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

003